Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Hugh M. O’Brodovich, M.D., Joins AIT’s Scientific Advisory Board

September 17, 2013

REHOVOT, Israel, September 17, 2013 /PRNewswire/ –

Israeli biomed company AIT (Advanced Inhalation Therapies Ltd.), a leader in the
development of nitric oxide therapeutics for the treatment of infectious respiratory
diseases, announced today the appointment of Hugh M. O’Brodovich, M.D.,to its scientific
advisory board.

Dr. O’Brodovich holds the position of Arline & Pete Harman Professor & Chair at the
Department of Pediatrics Stanford School of Medicine. Dr. O’Brodovich also hold the acts
as Pediatric Pulmonologist at the Division of Pulmonary Medicine, Adalyn Jay
Physician-in-Chief at Lucile Packard Children’s Hospital and Director of Child Health
Research Institute at Stanford University.

“I am very pleased to welcome Dr. Hugh M. O’Brodovich to AIT’s SAB. His tremendous
expertise and research in the field of respiratory distress and pulmonology will greatly
contribute to AIT in its successfull studies,” says David Greenberg M.D., Chief Medical
Officer at AIT and a Professor of Pediatrics and Infectious Diseases at the Soroka Medical
Center in Beer Sheva, Israel.

“I am honored to join AIT’s scientific advisory board,” said Dr. O’Brodovich. “I
believe the Company has a very bright future, given its promising therapeutic product
pipeline and drug development expertise. I am looking forward to working alongside AIT’s
experienced management team as they continue to advance the Company’s pipeline and forge
new strategic collaborations within the industry.”

AIT focuses on the development of unique nitric oxide formulations for the treatment
of respiratory infectious diseases, including bronchiolitis, cystic fibrosis, pneumonia
and asthma. The company is currently conducting Phase II trials for bronchiolitis in
infants. Mid-study results demonstrated the safety of AIT’s nitric oxide formulation in
children.

About AIT

AIT (http://www.ait-pharm.com) is an Israeli biomed company focused on the
development and commercialization of formulations from nitric oxide for the treatment of
infectious diseases. The company was founded in 2011 by Mor Research Applications, a
subsidiary of Clalit Health Services, Israel’s largest health management organization.

The company is conducting Phase II trials on bronchiolitis after successful completion
of Phase I trials. AIT develops products for the treatment of bronchiolitis, pneumonia,
cystic fibrosis and asthma.

        Contact information
        Racheli Vizman, COO, AIT
        2 Derech Meir Weisgal
        Rehovot 9632605, Israel
        E-mail: racheli@ait-pharm.com
        Direct: +972-8-684-3313
        Mobile: +972-52-565-9922

SOURCE AIT (Advanced Inhalation Therapies Ltd.)


Source: PR Newswire